Evidence map›Paper›PMID 41575679›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Prospective surveillance of Candida auris and assessment of diagnostic approaches in a Belgian hospital.

Kim Callebaut, Jorn Hellemans, Taeyang Chin, Katelijne Floré, Merijn Vanhee, Sylvia Snauwaert, Alexander Schauwvlieghe, Bram Dewulf, Marijke Reynders, Astrid Muyldermans

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kim CallebautDepartment of Medical Microbiology and Infection Prevention and Control, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium.
Jorn HellemansDepartment of Medical Microbiology and Infection Prevention and Control, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium.
Taeyang ChinDepartment of Medical Microbiology and Infection Prevention and Control, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium.
Katelijne FloréDepartment of Medical Microbiology and Infection Prevention and Control, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium.
Merijn VanheeDepartment of Medical Microbiology and Infection Prevention and Control, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium.
Sylvia SnauwaertDepartment of Clinical Haematology, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium.
Alexander SchauwvliegheDepartment of Clinical Haematology, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium.
Bram DewulfDepartment of Intensive Care Medicine, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium.
Marijke ReyndersDepartment of Medical Microbiology and Infection Prevention and Control, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium.
Astrid MuyldermansDepartment of Medical Microbiology and Infection Prevention and Control, AZ Sint-Jan Brugge AV, Ruddershove 10, Brugge, 8000, Belgium. astrid.muyldermans@azsintjan.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCandida auris is an emerging multidrug-resistant fungal pathogen known for its ability to cause healthcare-associated outbreaks. Although only sporadic cases have been reported in Belgium, increasing incidence in Europe highlights the need for early detection strategies. This study aimed to evaluate C. auris colonisation among high-risk patients and assess three detection methods.

methodsA total of 100 patients were screened using two eSwabs® per patient from: (i) axillae and groins, and (ii) nose, throat and perineum. Culture on CHROMagar Candida plus was compared with two molecular assays: Altostar® Candida auris PCR, and AurisID. Given the overlap in risk factors for C. auris and other multi-drug resistant organisms, the feasibility of culturing C. auris from an enrichment broth containing TSB and 2.5% sodium chloride, often used for MRSA enrichment, was evaluated.

resultsAnalytical evaluation showed high specificity of the molecular assays with no cross-reactivity to clinically relevant non-target yeasts. Culture on CHROMagar Candida plus appeared more sensitive than both molecular methods. No C. auris carriage was detected among all screened patients.

conclusionCandida auris was not detected in the screened population, indicating a very low or absent prevalence at present. However, surveillance is essential to ensure early recognition and address the risk of future spread.

Indexed as

CandidaCandida aurisCandidiasisAgedBelgiumFemaleHospitalsHumansMaleMiddle AgedPolymerase Chain ReactionProspective StudiesSensitivity and SpecificityAltostar Candida aurisAurisIDCandida aurisCHROMagar candida plusHospital epidemiology belgiumSurveillance

Identifiers

PMID41575679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.